Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors

Next Previous
X
Search
Trial Profile

A Phase 1 Study of CPI-1205 With Ipilimumab in Patients With Advanced Solid Tumors Followed by a Phase 2 Basket Study of CPI-1205 With Ipilimumab in Selected Tumor Types Previously Treated With PD-1 or PD-L1 Inhibitors

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lirametostat (Primary) ; Ipilimumab
  • Indications Bladder cancer; Malignant melanoma; Non-small cell lung cancer; Pelvic cancer; Renal cancer; Renal cell carcinoma; Solid tumours; Ureteral neoplasms; Urethral cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ORIOn-E
  • Sponsors Constellation Pharmaceuticals

    • Most Recent Events

    • 07 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 04 Jan 2019 Planned End Date changed from 1 Jun 2020 to 1 Dec 2019.
    • 04 Jan 2019 Planned primary completion date changed from 1 Jun 2020 to 1 Dec 2019.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top